Overview: Prothrombin Mutation TestIntroduction: The Prothrombin Mutation Test detects prothrombin gene mutations to diagnose clotting risk, causing thrombosis. Aligned with 2023 ISTH guidelines, it uses PCR for high specificity, supporting genetic screening. This test is critical for guiding risk assessment, treatment planning, and improving outcomes in coagulation for patients with suspected thrombophilia.
Other Names: Prothrombin Genotyping Assay, G20210A Mutation Test.
FDA Status: Laboratory-developed test (LDT), meeting coagulation standards for diagnostic accuracy.
Historical Milestone: Prothrombin mutation testing began in the 1990s with thrombophilia research. PCR methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects prothrombin gene mutations to diagnose clotting risk, guides treatment, and evaluates patients with thrombosis.
Test Parameters: 1. Prothrombin Gene Mutation
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of thrombosis or family clotting disorders.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document thrombosis, family history of clotting disorders, or cardiovascular events. Include current medications, especially anticoagulants.
Consent: Written consent required, detailing the tests purpose, clotting risk implications, and risks of sample collection.
Procedural Considerations: Uses PCR to detect prothrombin G20210A mutations. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for thrombophilia diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Positive mutation confirms increased clotting risk, guiding anticoagulant prophylaxis. Negative results may require other thrombophilia tests.
Specialist Consultation: Consult a hematologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Factor V Leiden, D-dimer, or Protein C/S testing to confirm thrombophilia diagnosis.
Test Limitations: Mutation alone does not predict thrombosis; clinical correlation is needed. Sample quality affects sensitivity.
References: ISTH Thrombophilia Guidelines, 2023; Journal of Thrombosis and Haemostasis, Poort SR, 2022.
